The AMNOG-Monitor provides all relevant information on early benefit assessment and price negotiations, updated daily. A solid foundation for Market Access, HTA, Medical, Business Development, and Pricing.
13. November 2026
The European health technology assessment has been started for the following three new oncology active substances:
10. November 2026
At ISPOR Europe 2026 in Vienna (8–11 November 2026), Tomeczkowski et al. presented an analysis of 962 benefit assessment dossiers completed between July 2011 and July 2026. Orphan drugs whose …
07. November 2026
At this year’s “Pharma Trends 2027” conference organised by Forum Institut, Matthias Hiller (CDU), member of the Health Committee of the German Bundestag, discussed the criteria of the planned location …
Key data from all AMNOG decisions, summarized in a compact and structured format.
Analyze your own research questions by filtering across more than 120 parameters.
Fast, quality-assured analysis of original documents such as dossiers, G-BA decisions, arbitration rulings, and clinical trials.
Price trends for all AMNOG drugs at PZN level and for annual therapy costs. Tracking of all appropriate comparator therapies (ZVT) and their weighting (on request).
EU dossiers and JCAs will be integrated into the AMNOG-Monitor as soon as the first ones become available.
Export analysis results to Excel, PowerPoint, or Word with links back to the AMNOG-Monitor. Save standard queries for price changes or new indications using bookmarks.
